CR20140095A - AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME - Google Patents

AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Info

Publication number
CR20140095A
CR20140095A CR20140095A CR20140095A CR20140095A CR 20140095 A CR20140095 A CR 20140095A CR 20140095 A CR20140095 A CR 20140095A CR 20140095 A CR20140095 A CR 20140095A CR 20140095 A CR20140095 A CR 20140095A
Authority
CR
Costa Rica
Prior art keywords
methods
cytotoxic
antigen
specific
same
Prior art date
Application number
CR20140095A
Other languages
Spanish (es)
Inventor
Gillian Payne
Philip Chun
Daniel Tavares
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Priority to CR20140095A priority Critical patent/CR20140095A/en
Publication of CR20140095A publication Critical patent/CR20140095A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen conjugados citotóxicos que comprenden un agente de enlace celular y un agente citotóxico, composiciones terapéuticas que comprenden el conjugado, métodos para usar los conjugados en la inhibición del crecimiento celular y el tratamiento de la enfermedad, y un equipo de comprende el conjugado citotóxico en todas las modalidades de la invención. En particular, el agente de enlace celular es un anticuerpo monoclonal, y fragmentos de enlace de epítope del mismo, que reconoce y enlaza el glicótopo CA6. La presente invención también está dirigida a versiones humanizadas o recubiertas de DS6, un anticuerpo monoclonal anti-CA6 murino, y fragmentos de enlace de epítope del mismo.Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and treatment of the disease, and a kit comprising the cytotoxic conjugate are described in all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope binding fragments thereof, which recognizes and binds the CA6 glycopepo. The present invention is also directed to humanized or coated versions of DS6, a murine anti-CA6 monoclonal antibody, and epitope binding fragments thereof.

CR20140095A 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME CR20140095A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR20140095A CR20140095A (en) 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CR20140095A CR20140095A (en) 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Publications (1)

Publication Number Publication Date
CR20140095A true CR20140095A (en) 2014-03-28

Family

ID=51359547

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140095A CR20140095A (en) 2014-02-26 2014-02-26 AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME

Country Status (1)

Country Link
CR (1) CR20140095A (en)

Similar Documents

Publication Publication Date Title
MX2018012757A (en) Agonistic antibodies that bind human cd40 and uses thereof.
EA201892294A1 (en) ANTIBODIES AND COMPOSITIONS AGAINST TIM-3
PE20210289A1 (en) ANTI-CD25 FOR THE DEPLETION OF SPECIFIC TUMOR CELLS
ECSP18005520A (en) FACTOR XI ANTIBODIES AND METHODS OF USE
UY36401A (en) ANTIBODY-DRUG CONJUGATES
ECSP18096095A (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM
CO2018000809A2 (en) Antibodies for cd40
AR107442A1 (en) ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER
ECSP088241A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
GT201200318A (en) ANTIBODIES TO GDF8 HUMAN
ECSP066294A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
EA201692100A8 (en) NEW ANTIBODIES AGAINST RNF43 AND METHODS OF THEIR APPLICATION
CO2019007846A2 (en) Anti-neuropilin antigen binding proteins and their methods of use
EA201790529A1 (en) NEW ANTIBODIES AGAINST MFI2 AND METHODS OF THEIR APPLICATION
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
EA201891299A1 (en) THERAPEUTIC ANTIBODIES TO CD9
CL2017000212A1 (en) Angiopoietin 4-like anti-protein antibodies and methods of use
CL2018001238A1 (en) Specific binding molecules for asct2 and their uses
UY37598A (en) MIMETIC ANTIBODIES OF FGF21 AND USES OF THE SAME
AR101671A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA-4 (ANGPTL4) AND METHODS OF USE
EA201992318A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN
BR112018000909A2 (en) il22 immunoconjugates
CR20140095A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
EA202190504A1 (en) METHODS FOR TREATMENT OF PSORIASIS
UY36922A (en) ASGR INHIBITORS